 ASLAN Pharmaceuticals Nasdaq: ASLN, TPEx:6497, a clinical-stage oncology and immunology focused biopharma company, today announced that it has commenced an underwritten public offering of its American Depositary Shares ADSs representing ordinary shares. In addition, ASLAN expects to grant the underwriter an option, exercisable at any time through and until one day before the potential closing date of this offering, to purchase up to an additional 15 of the ADSs being offered on the same terms and conditions. All ADSs to be sold in the offering will be offered by ASLAN. 